SVG (saphenous vein graft) protection device edges closer in Europe:
This article was originally published in Clinica
Kensey Nash has received a recommendation from the European regulatory authority, TUV Rheinland, for CE-mark approval of its TriActiv balloon protected flush extraction system (see Clinica 978, p 16). The device, which is designed to prevent heart attacks during the treatment of bypass surgery patients with blocked saphenous vein grafts (SVG), has been shown to reduce complication rates from around 15-20% to just 6.9%, according to clinical trial data, says the Exton, Philadelphia firm.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.